Unione Europea - finlandese - EMA (European Medicines Agency)

laboratorios syva, s.a.u. - inaktivoitu bluetongue-virus, serotyyppi 1, kanta alg2006/01 e1 inaktivoitu bluetongue-virus, serotyyppi 4, kanta btv-4/spa-1/2004, inaktivoitu bluetongue-virus, serotyyppi 8, kanta bel2006/01 - inaktivoidut virusrokotteet - cattle; sheep - aktiivinen immunisointi lampaita estää viremiaa ja vähentää kliinisiä oireita ja vaurioita aiheuttama bluetongue-viruksen serotyypin 1 ja/tai 8 ja/tai vähentää viremia* ja kliinisiä oireita ja vaurioita aiheuttama bluetongue-virus, serotyyppi 4for aktiivinen immunisaatio nautojen estää viremiaa aiheuttama bluetongue-viruksen serotyypin 1 ja/tai 8 ja/tai vähentää viremia* aiheuttama bluetongue-virus, serotyyppi 4.

Unione Europea - finlandese - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - siat - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Unione Europea - finlandese - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetyylifumaraatti - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

laboratorios liconsa s.a. - fampridine - depottabletti - 10 mg - fampridiini

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

vifor france - tehtävä: polymaltosum monimutkainen - tipat, liuos - 2,5 mg/tippa - rautaoksidipolymaltoosikompleksit

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

vifor france - tehtävä: polymaltosum monimutkainen - purutabletti - 100 mg - rautaoksidipolymaltoosikompleksit

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

vifor france - iron(iii)-hydroxide polymaltose complex - tipat, liuos - 50 mg/ml - rautaoksidipolymaltoosikompleksit

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

vifor france - iron(iii)-hydroxide polymaltose complex - purutabletti - 100 mg - rautaoksidipolymaltoosikompleksit

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

vifor france - iron(iii)hydroxide sucrose complex - injektioneste, liuos/infuusiokonsentraatti, liuosta varten - 20 mg/ml - rauta

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

laboratoires besins international - dienogest - tabletti - 2 mg - dienogesti